Selling on Lightspeed Scanner gives sales associates the power to close sales on the move; improving the customer experience and eliminating the friction of in-store line up’s

MONTREAL, Jan. 14, 2025 /PRNewswire/ – Lightspeed Commerce Inc. (NYSE: LSPD) (TSX: LSPD) (“Lightspeed”), the one-stop commerce platform empowering merchants to provide the best omnichannel experiences, introduces a new game-changing feature for retailers designed to eliminate the frustration of long lines and interrupted shopping experiences by enabling sales associates to complete purchases where the customer is. Selling on Lightspeed Scanner – available on iPhone, is the latest Lightspeed innovation helping retailers create a more customized, frictionless experience for their customers.

With 39% of shoppers citing great customer service as the top reason they’re willing to spend more–according to Lightspeed’s State of Retail 2024 Report—this enhancement addresses two common pain points in retail: long wait times and inefficient service.

“This launch marks a pivotal moment for retailers,” said Dax Dasilva, CEO of Lightspeed. “By closing the sale directly with the customer—no lines, no disruptions—retailers are meeting shoppers’ needs for speed and personalization, all while creating moments of delight that turn transactions into lasting relationships.”

Research shows that 42% of shoppers would be open to VIP shopping experiences such as skipping lines and personalized shopping recommendations. By empowering sales associates to serve customers end-to-end, Lightspeed helps retailers overcome challenges, ensuring that the shopping experience is fast, flexible, personalized and frictionless.

The new Lightspeed Scanner feature transforms traditional in-store shopping by allowing retailers to:

Queue busting: Streamline the shopping experience by letting customers check out where they are, avoiding the frustration of queuing at registers.Maximize associate impact: Equip sales teams with the tools to offer personalized consultations, check inventory, and process transactions without leaving the customer’s side.Sell seamlessly in any environment: Extend seamless service to diverse selling environments like pop-ups, events, or large retail spaces, offering flexibility and convenience.

“The new selling function on Lightspeed Scanner for X-Series with Tap to Pay has given our team peace of mind,” says Cody Coleman, Owner of Do It Yourself Pest and Weed.

It provides a backup that is ready when the unexpected occurs, without the added cost of additional hardware. Plus, we now have the flexibility to quickly add an additional register when it gets busy in the store.”

Lightspeed has consistently demonstrated its commitment to transforming the retail experience through innovation. With each new product launch, Lightspeed empowers retailers with tools designed for modern challenges. Recent advancements, like Retail Insights, improved inventory management through real-time tracking, and the enhanced Homebase integration offering a seamless solution for employee and time management, showcase Lightspeed’s drive to push boundaries.

Lightspeed is not just adapting to the future of retail but contributing to its design, ensuring customers can stay ahead in a dynamic market.

Retailers eager to enhance their operations and reimagine their in-store experience can visit this page for more information.

About Lightspeed

Powering the businesses that are the backbone of the global economy, Lightspeed’s one-stop commerce platform helps merchants innovate to simplify, scale, and provide exceptional omnichannel customer experiences. Our cloud commerce solution transforms and unifies online and physical operations, multichannel sales, expansion to new locations, global payments, financial solutions, and connection to supplier networks.

Founded in Montréal, Canada in 2005, Lightspeed is dual-listed on the New York Stock Exchange and Toronto Stock Exchange (NYSE: LSPD) (TSX: LSPD). With teams across North America, Europe, and Asia Pacific, the company serves retail, hospitality, and golf businesses in over 100 countries.

Follow us on social media: LinkedIn, Facebook, Instagram, YouTube, and X.

Forward-Looking Statements

This news release may include forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”), including information regarding Lightspeed’s partnerships, product offerings and planned product roadmap. Forward-looking statements are statements that are predictive in nature, depend upon or refer to future events or conditions and are identified by words such as “will”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” or similar expressions concerning matters that are not historical facts. Such statements are based on current expectations of Lightspeed’s management and inherently involve numerous risks and uncertainties, known and unknown, including economic factors. A number of risks, uncertainties and other factors may cause actual results to differ materially from the forward-looking statements contained in this news release, including, among other factors, those risk factors identified in our most recent Management’s Discussion and Analysis of Financial Condition and Results of Operations, under “Risk Factors” in our most recent Annual Information Form, and in our other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR+ at www.sedarplus.com and on EDGAR at www.sec.gov. Readers are cautioned to consider these and other factors carefully when making decisions with respect to Lightspeed’s subordinate voting shares and not to place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are not guarantees of future performance and, while forward-looking statements are based on certain assumptions that Lightspeed considers reasonable, actual events and results could differ materially from those expressed or implied by forward-looking statements made by Lightspeed. Except as may be expressly required by applicable law, Lightspeed does not undertake any obligation to update publicly or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lightspeed-transforms-the-retail-experience-with-new-mobile-selling-application-302349850.html

SOURCE Lightspeed Commerce Inc.

The Women-Owned Small Business will offer its full range of services in the Management and Advisory, and Technology and Engineering domains

ROCKVILLE, Md., Jan. 14, 2025 /PRNewswire/ — DSFederal, a leading provider of data science and digital solutions, is pleased to announce its award of the One Acquisition Solution for Integrated Services (“OASIS+”) Governmentwide Acquisition Indefinite Delivery/Indefinite Quantity (“GWAC ID/IQ”) contract. Under this contract, DSFederal will be eligible to provide its services within the Management & Advisory, and Technology & Engineering domains.

“This award reflects DSFederal’s reputation for providing trusted, effective, and innovative solutions that help meet and solve the growing demands and challenges of Federal clients through vehicles like OASIS+” said Sophia Parker, Owner & CEO of DSFederal. 

Expanded Opportunities to Make a Positive Impact

Recipients of the OASIS+ GWAC contract are eligible to provide a wide range of services to Federal agencies within their respective domains. DSFederal’s inclusion in the contract’s Unrestricted, Small Business, and Women-Owned Small Business (WOSB) pools will enable the company to offer critical services in multiple areas.

Management and Advisory: DSFederal will provide consulting and advisory services to Federal agency operations, leveraging business intelligence, interactive dashboards, and data-driven decision making to enhance overall performance and efficiency.Technology and Engineering: DSFederal will deliver advanced technology solutions and support, including IT support services (ITSS) and Drupal web development, driving innovation and enabling the modernization of Federal systems and infrastructures.

This award reflects DSFederal’s commitment to providing effective, data-driven solutions that meet the unique needs of the Federal government. With its technical expertise combined with a successful history of delivering federal project solutions, DSFederal is well-positioned to support a wide range of federal initiatives across both established and emerging areas.

For more information about DSFederal, please visit: https://www.dsfederal.com/.

About DSFederal

DSFederal provides transformative technical solutions and strategic support for the Federal Government and for HHS. Our highly specialized data science team, deep public health expertise combined with a broad technology skillset and partnerships with innovative organizations in the private sector help us to connect the dots between data and people, delivering impactful insights with real-life applications.

Our firm is ISO 9001, 20001, 27001 certified and CMMI Level 3 for service and development, proving our commitment to consistently high-quality standards and ensuring customer satisfaction. Our highly experienced professionals partner with 50+ federal clients across more than 80 projects. Our people are united by one mission – to improve human life through transformative solutions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dsfederal-awarded-oasis-gwac-idiq-contract-302349772.html

SOURCE DSFederal

“‘Special K’: The Science & Stigma of Ketamine” on CNN, hosted by Dr. Sanjay GuptaDavid Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry fieldKadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closingDr. Feifel is expected to join HOPE as Chief Medical Innovation Officer

MIAMI, Jan. 14, 2025 /PRNewswire/ — HOPE Therapeutics™, Inc., (“HOPE”), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (“NRx”, and collectively with HOPE, the “Company”) (Nasdaq:NRXP), today alerted investors that Kadima Neuropsychiatry Institute’s Founder David Feifel, MD PHD was featured as an expert in a program on ketamine entitled “‘Special K’: The Science & Stigma of Ketamine” on CNN, hosted by Dr. Sanjay Gupta. HOPE previously announced that Kadima is identified as the Company’s planned flagship clinic acquisition, upon closing of the transaction.

Dr. Feifel, a global leader in interventional psychiatry, has accepted a future role as Chief Medical Innovation Officer in conjunction with the previously announced planned acquisition of Kadima by HOPE. The acquisition is subject to completion of financial audits and standard closing conditions.

In his comments, Dr. Feifel supported use the of ketamine in appropriate patients but emphasized the need for appropriate psychiatric supervision in a controlled setting – a view that HOPE wholeheartedly shares. This appearance with Dr. Gupta follows his appearance on another of Dr. Gupta’s programs, “The Wild West of Ketamine Treatment” in August of last year.

“The recent, tragic death of Mathew Perry underscores the need for people with depression to have access to psychiatric centers of excellence where they can receive ketamine and other advanced treatments at the highest standard of medical care,” said David Feifel. “I plan to bring this same vision for use of ketamine and other interventional psychiatry treatment methods that made my clinic, Kadima, an industry gold-standard, to the HOPE network, upon joining the Company.”

About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional  psychiatry clinics to offer ketamine transcranial magnetic stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obtaining financing necessary to consummate the acquisition. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, liquidity, Hope Therapeutic’s ability to consummate the acquisitions of providers for its national network, the Company’s ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company’s ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-alert-investors-to-sanjay-guptacnn-program-on-ketamine-featuring-kadima-neuropsychiatry-institute-founder-dr-david-feifel-302350245.html

SOURCE NRx Pharmaceuticals, Inc.